Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker RPRX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Abigail P. Johnson | 19.29M | 4.3% | SCHEDULE 13G/A ↗ |
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | FMR LLC | 19.29M | 4.3% | SCHEDULE 13G/A ↗ |
| Aug 17, 2026 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | Legorreta Investments, LLC | 37.54M | 7.8% | SCHEDULE 13D/A ↗ |
| Aug 17, 2026 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | G. Pablo Legorreta | 101.79M | 18.7% | SCHEDULE 13D/A ↗ |
| Jun 16, 2026 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | Achille G. Severgnini | 21.37M | 4.8% | SCHEDULE 13D/A ↗ |
| Jun 16, 2026 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | Butterfield Fiduciary Administrators Trust Company Limited | 21.37M | 4.8% | SCHEDULE 13D/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Capital International Investors | 37.77M | 8.8% | SCHEDULE 13G/A ↗ |
| Feb 20, 2026 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | Achille G. Severgnini | 24.22M | 5.7% | SCHEDULE 13D/A ↗ |
| Feb 20, 2026 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | R & H Trust Co. (Guernsey) Limited | 24.22M | 5.7% | SCHEDULE 13D/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Capital International Investors | 32.75M | 7.7% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Capital International Investors | 28.51M | 6.6% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Abigail P. Johnson | 27.90M | 6.5% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | FMR LLC | 27.90M | 6.5% | SCHEDULE 13G/A ↗ |
| Oct 30, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | The Vanguard Group | 10.94M | 2.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | GA RP Holding, Ltd. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | GAP (Bermuda) L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic GenPar (Bermuda), L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic (Lux) S.a r.l. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic GenPar (Lux) SCSp | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic Partners (Lux) SCSp | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic Partners (Bermuda) IV, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic Partners (Bermuda) EU, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic GenPar, L.P. | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic (SPV) GP, LLC | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | GAP Coinvestments V, LLC | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | GAP Coinvestments IV, LLC | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | GAP Coinvestments III, LLC | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | GAP Coinvestments CDA, L.P. | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic Partners AIV-1 B, L.P. | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic Partners AIV-1 A, L.P. | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | GA RP Holding, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic (RP) Collections, LLC | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | General Atlantic, L.P. | 14.24M | 3.2% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G | RPRX Royalty Pharma plc | Capital International Investors | 23.11M | 5.5% | SCHEDULE 13G ↗ |
| Aug 5, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Morgan Stanley Investment Management Inc. | 35.86M | 8.5% | SCHEDULE 13G/A ↗ |
| Aug 5, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Morgan Stanley | 38.91M | 9.2% | SCHEDULE 13G/A ↗ |
| May 23, 2025 | SCHEDULE 13D | RPRX Royalty Pharma plc | Legorreta Investments, LLC | 37.54M | 8.1% | SCHEDULE 13D ↗ |
| May 23, 2025 | SCHEDULE 13D | RPRX Royalty Pharma plc | G. Pablo Legorreta | 103.11M | 19.7% | SCHEDULE 13D ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Abigail P. Johnson | 39.25M | 9.1% | SCHEDULE 13G/A ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | FMR LLC | 39.25M | 9.1% | SCHEDULE 13G/A ↗ |
| May 2, 2025 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | Achille G. Severgnini | 29.93M | 6.9% | SCHEDULE 13D/A ↗ |
| May 2, 2025 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | R & H Trust Co. (Guernsey) Limited | 29.93M | 6.9% | SCHEDULE 13D/A ↗ |
| Feb 21, 2025 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | Achille G. Severgnini | 36.00M | 8.3% | SCHEDULE 13D/A ↗ |
| Feb 21, 2025 | SCHEDULE 13D/A (amended) | RPRX Royalty Pharma plc | R & H Trust Co. (Guernsey) Limited | 36.00M | 8.3% | SCHEDULE 13D/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | Abigail P. Johnson | 26.31M | 5.9% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | RPRX Royalty Pharma plc | FMR LLC | 26.31M | 5.9% | SCHEDULE 13G/A ↗ |
| Feb 4, 2025 | SCHEDULE 13G | RPRX Royalty Pharma plc | BlackRock, Inc. | 25.45M | 5.7% | SCHEDULE 13G ↗ |
47 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:32 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances